Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Donata BackhausMadlen JentzschLara BischofDominic BrauerChristina WilhelmJulia SchulzGeorg-Nikolaus FrankeWolfram PönischVladan VucinicUwe PlatzbeckerSebastian SchwindPublished in: Cancers (2021)
Outcomes of trisomy 8 patients after allogeneic HSCT did not compare unfavorably to that of other AML patients following allogeneic HSCT. Rather than the presence or absence of a trisomy 8, additional genetic aberrations and MRD at HSCT define outcome differences and aid in informed treatment decisions.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- acute myeloid leukemia
- newly diagnosed
- hematopoietic stem cell
- chronic kidney disease
- stem cell transplantation
- acute lymphoblastic leukemia
- peritoneal dialysis
- prognostic factors
- gene expression
- metabolic syndrome
- copy number
- dna methylation
- insulin resistance
- patient reported
- glycemic control
- replacement therapy